Current Management of Stage IIIA Non-Small Cell Lung Cancer: A Changing Paradigm (November 10, 2022)

The management of stage IIIA non-small cell lung cancer (NSCLC) is evolving in the era of immune checkpoint inhibitor therapy. In the past, there has been a great deal of controversy regarding the optimal management of patients with N2 nodal metastasis at the time of diagnosis of NSCLC. There are some new questions to address when considering the results of the Checkmate 816 and the NADIM II clinical trials which demonstrated improved disease-free survival and overall survival with neoadjuvant combined chemotherapy and Nivolumab. In addition, what is the role for perioperative radiation in resectable stage IIIA NSCLC in patients who receive neoadjuvant immunotherapy? In this webinar, the moderators and an interdisciplinary panel from major cancer centers across the country discuss the current management of resectable stage IIIA NSCLC in the era of immune checkpoint inhibitor therapy. Panelists: David P. Carbone, MD, PhD​, Jessica Donington, MD​, MSCR (moderator), Nathaniel R. Evans III, MD (moderator), Robert E. Merritt, MD​, and Maria Werner-Wasik, MD

[@judylantz4929]

I am 76 year old woman with 3A stage lung cancer due to a 7.5 cm tumour which was resectable (first line of treatment) with no lymph involvement. I followed surgery with chemotherapy and immunotherapy PDL1 (100%). I want to thank everyone for the team work that goes into this treatment. My team has been amazing !

[@r.keithyoung]

I am amazed at how informative this session is...... AND..... how there are no questions/comments in this section. ???

[@weaverdreams]

Prognosis after 2a dx & lobe removal?

[@robsantos7387]

𝖕𝖗𝖔𝖒𝖔𝖘𝖒